

DOCKETS MANAGEMENT BRANCH (HFA-305)
FOOD AND DRUG ADMINISTRATION
5630 FISHERS LANE ROOM 1061
ROCKVILLE MD 20852
Docket No. 98N1265
FDADockets@bangat.fda.gov

3-24-99

FDA:

As a consumer of healthcare services, I wish to register my objections to 5613 '99 APR 13 NO :22
provisions of the Memorandum of Understanding (MOU) as published by the FDA on
January 21, 1999. I thank the Food and Drug Administration for making it
possible to purchase prescription products individually compounded for my
needs. I also appreciate the option of using products made from natural
ingredients as opposed to patented synthetics. Unfortunately, the restrictions
the MOU places on compounding pharmacies have the effect of denying many
consumers the option of using these valuable products, and the potential to
jeopardize my right to buy the products I choose from the pharmacists my
doctor and I trust most.

Specific sections of concern include all of section MOU II-C and all of III-C:
Distribution of inordinate Amounts of Compounded Drugs. These sections can, by
placing restrictions on the amounts that can be sold out of state,
discriminate against consumers who do not live in the state where the products
preferred by their physicians are compounded. Economically, they discriminate
against health-care consumers who cannot afford to travel and obtain care in
the state where their preferred compounding pharmacy is located.

By threatening the economic survival of pharmacies whose superior products
draw physicians and customers from out of state, the MOU threatens to make the
superior products unavailable to consumers who need them. Doing so would
unfairly restrict consumer choice. Federal restrictions in place effectively
deny these products to the vast majority of consumers. Section II-B of the MOU
refers to restrictions on a compounding pharmacy's right to promote its
products and services. The result is that most consumers don't know they
exist, and the only physicians who know about them are the enlightened
physicians who take the initiative to seek them out. By contrast, FDA does not
prevent manufacturers of patented, synthetic, one-size-fits-all preparations
from large-scale advertising designed to persuade consumers to tell their
physicians to prescribe their drugs. often in spite of a nightmare litany of
side effects, adverse reactions, and contraindications. FDA allows advertising
of OTC drugs available even to children without a prescription.

Please amend the memorandum of understanding to avoid jeopardizing my right to
buy products compounded for my needs anywhere I choose in the United States. I
want no restrictions to delivery of a compounded medication prescribed for me,
regardless of where I may live or travel.

Thank you !

Signed:

Address:

Marie Lombard Allene PhD
11500 Wordsworth Rd
Moreno Valley Calif 92557


98N-1265

C1054

M Comstock

11500 Wordsworth Rd

Moreno Valley Ca 92557



Docket Mgmt Branch HFA-305
FDA

5630 Fishers Lane Room 1061

Rockville, MD 20852

Docket # 98N1265

20857/0001

